---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066911"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:03:42.288851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M

## Summary
- Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.
- Gross profit margin 84.7%; RECELL-only margin 86.4%; expects ~$2.5M lower quarterly opex going forward.
- Launched RECELL GO mini in Feb; nationwide Cohealyx launch on Apr 1 expanding addressable U.S. market to >$3.5B.
- Obtained OrbiMed revenue covenant waiver for Q1; Q2 trailing 12-month covenant set at $78.0M.
- Expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-066911
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017025066911/0000950170-25-066911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017025066911/rcel-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066911
- JSON: https://secwatch.observer/filing/0000950170-25-066911.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.